Potential Clinical Implications of Senotherapies for Cardiovascular Disease

Overview

Journal Circ J

Specialty Cardiology & Vascular Diseases

Date 2023 Oct 25

PMID 37880106

Authors

Masayoshi Suda

Goro Katsuumi

Tamar Tchkonia

James L Kirkland

Tohru Minamino

Affiliations

Soon will be listed here.

Abstract

Aging is a major risk factor for cardiovascular diseases (CVDs) and accumulating evidence indicates that biological aging has a significant effect on the onset and progression of CVDs. In recent years, therapies targeting senescent cells (senotherapies), particularly senolytics that selectively eliminate senescent cells, have been developed and show promise for treating geriatric syndromes and age-associated diseases, including CVDs. In 2 pilot studies published in 2019 the senolytic combination, dasatinib plus quercetin, improved physical function in patients with idiopathic pulmonary fibrosis and eliminated senescent cells from adipose tissue in patients with diabetic kidney disease. More than 30 clinical trials using senolytics are currently underway or planned. In preclinical CVD models, senolytics appear to improve heart failure, ischemic heart disease, valvular heart disease, atherosclerosis, aortic aneurysm, vascular dysfunction, dialysis arteriovenous fistula patency, and pre-eclampsia. Because senotherapies are completely different strategies from existing treatment paradigms, they might alleviate diseases for which there are no current effective treatments or they could be used in addition to current therapies to enhance efficacy. Moreover, senotherapies might delay, prevent, alleviate or treat multiple diseases in the elderly and reduce polypharmacy, because senotherapies target fundamental aging mechanisms. We comprehensively summarize the preclinical evidence about senotherapies for CVDs and discuss future prospects for their clinical application.

Citing Articles

Roadmap for alleviating the manifestations of ageing in the cardiovascular system.

Liberale L, Tual-Chalot S, Sedej S, Ministrini S, Georgiopoulos G, Grunewald M Nat Rev Cardiol. 2025; .

PMID: 39972009 DOI: 10.1038/s41569-025-01130-5.

The Intersection of Epigenetics and Senolytics in Mechanisms of Aging and Therapeutic Approaches.

Burdusel D, Doeppner T, Surugiu R, Hermann D, Olaru D, Popa-Wagner A Biomolecules. 2025; 15(1).

PMID: 39858413 PMC: 11762397. DOI: 10.3390/biom15010018.

A Dual Role of the Senescence Marker P16Ink4a in Liver Endothelial Cell Function.

Wagner K, Safwan-Zaiter H, Wagner N Cells. 2024; 13(23).

PMID: 39682678 PMC: 11640762. DOI: 10.3390/cells13231929.

Senescent cell depletion alleviates obesity-related metabolic and cardiac disorders.

de Oliveira Silva T, Lunardon G, Lino C, de Almeida Silva A, Zhang S, Irigoyen M Mol Metab. 2024; 91():102065.

PMID: 39557194 PMC: 11636344. DOI: 10.1016/j.molmet.2024.102065.

Cardiovascular aging: spotlight on mitochondria.

Ali M, Gioscia-Ryan R, Yang D, Sutton N, Tyrrell D Am J Physiol Heart Circ Physiol. 2023; 326(2):H317-H333.

PMID: 38038719 PMC: 11219063. DOI: 10.1152/ajpheart.00632.2023.

References

Xie J, Chen Y, Hu C, Pan Q, Wang B, Li X . Premature senescence of cardiac fibroblasts and atrial fibrosis in patients with atrial fibrillation. Oncotarget. 2017; 8(35):57981-57990. PMC: 5601627. DOI: 10.18632/oncotarget.19853. View

Lakshminarayan K, Solid C, Collins A, Anderson D, Herzog C . Atrial fibrillation and stroke in the general medicare population: a 10-year perspective (1992 to 2002). Stroke. 2006; 37(8):1969-74. DOI: 10.1161/01.STR.0000230607.07928.17. View

Panchal S, Poudyal H, Brown L . Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats. J Nutr. 2012; 142(6):1026-32. DOI: 10.3945/jn.111.157263. View

Triana-Martinez F, Picallos-Rabina P, Da Silva-Alvarez S, Pietrocola F, Llanos S, Rodilla V . Identification and characterization of Cardiac Glycosides as senolytic compounds. Nat Commun. 2019; 10(1):4731. PMC: 6803708. DOI: 10.1038/s41467-019-12888-x. View

Childs B, Baker D, Wijshake T, Conover C, Campisi J, van Deursen J . Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science. 2016; 354(6311):472-477. PMC: 5112585. DOI: 10.1126/science.aaf6659. View

Hu C, Zhang X, Teng T, Ma Z, Tang Q . Cellular Senescence in Cardiovascular Diseases: A Systematic Review. Aging Dis. 2022; 13(1):103-128. PMC: 8782554. DOI: 10.14336/AD.2021.0927. View

Suda M, Shimizu I, Katsuumi G, Yoshida Y, Hayashi Y, Ikegami R . Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. Nat Aging. 2023; 1(12):1117-1126. DOI: 10.1038/s43587-021-00151-2. View

Spilman P, Podlutskaya N, Hart M, Debnath J, Gorostiza O, Bredesen D . Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One. 2010; 5(4):e9979. PMC: 2848616. DOI: 10.1371/journal.pone.0009979. View

Laberge R, Sun Y, Orjalo A, Patil C, Freund A, Zhou L . MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol. 2015; 17(8):1049-61. PMC: 4691706. DOI: 10.1038/ncb3195. View

10.

Ramos F, Chen S, Garelick M, Dai D, Liao C, Schreiber K . Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci Transl Med. 2012; 4(144):144ra103. PMC: 3613228. DOI: 10.1126/scitranslmed.3003802. View

11.

Wang B, Wang L, Gasek N, Zhou Y, Kim T, Guo C . An inducible -Cre mouse model to monitor and manipulate -highly-expressing senescent cells . Nat Aging. 2022; 1(10):962-973. PMC: 8746571. DOI: 10.1038/s43587-021-00107-6. View

12.

He S, Sharpless N . Senescence in Health and Disease. Cell. 2017; 169(6):1000-1011. PMC: 5643029. DOI: 10.1016/j.cell.2017.05.015. View

13.

Ho J, Enserro D, Brouwers F, Kizer J, Shah S, Psaty B . Predicting Heart Failure With Preserved and Reduced Ejection Fraction: The International Collaboration on Heart Failure Subtypes. Circ Heart Fail. 2016; 9(6). PMC: 4902276. DOI: 10.1161/CIRCHEARTFAILURE.115.003116. View

14.

Dookun E, Passos J, Arthur H, Richardson G . Therapeutic Potential of Senolytics in Cardiovascular Disease. Cardiovasc Drugs Ther. 2020; 36(1):187-196. PMC: 8770386. DOI: 10.1007/s10557-020-07075-w. View

15.

Liu Y, Sanoff H, Cho H, Burd C, Torrice C, Ibrahim J . Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell. 2009; 8(4):439-48. PMC: 2752333. DOI: 10.1111/j.1474-9726.2009.00489.x. View

16.

Wang G, Zhu X, Xie W, Han P, Li K, Sun Z . Rad as a novel regulator of excitation-contraction coupling and beta-adrenergic signaling in heart. Circ Res. 2009; 106(2):317-27. DOI: 10.1161/CIRCRESAHA.109.208272. View

17.

Moiseeva O, Deschenes-Simard X, St-Germain E, Igelmann S, Huot G, Cadar A . Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation. Aging Cell. 2013; 12(3):489-98. DOI: 10.1111/acel.12075. View

18.

Tchkonia T, Palmer A, Kirkland J . New Horizons: Novel Approaches to Enhance Healthspan Through Targeting Cellular Senescence and Related Aging Mechanisms. J Clin Endocrinol Metab. 2020; 106(3):e1481-e1487. PMC: 7947756. DOI: 10.1210/clinem/dgaa728. View

19.

Kirkland J, Tchkonia T . Cellular Senescence: A Translational Perspective. EBioMedicine. 2017; 21:21-28. PMC: 5514381. DOI: 10.1016/j.ebiom.2017.04.013. View

20.

Van Der Feen D, Bossers G, Hagdorn Q, Moonen J, Kurakula K, Szulcek R . Cellular senescence impairs the reversibility of pulmonary arterial hypertension. Sci Transl Med. 2020; 12(554). PMC: 7891555. DOI: 10.1126/scitranslmed.aaw4974. View